AstraZeneca to acquire Amolyt Pharma for up to US$1.05bn
Under the agreement set to close in Q3/2024, AstraZeneca will acquire Amolyt Pharma for US$800m upfront and potential milestone payments of US$250m....
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Obesity: Arecor Therapeutics partners with TRx Biosciences
The collaboration of the biopharma and drug discovery specialists targets a potential US$80bn market of obesity drugs, according to Bloomberg...
AC Immune and Takeda ink US$2.1bn biobucks deal
Under the US$2.1bn biobucks deal, Pharma giant Takeda gets the globally exclusive right to licence AC Immune SA's active immunisation therapy...
Nordic Bioproducts Group opens its first production facility
Nordic Bioproduct’s commercial-scale manufacturing site is expected to create €40m in revenue in the first full operating year. In...
Senisca Ltd raises £3.7m seed money
The proceeds of Senisca’s latest funding round led by Lifespan Vision Venture will support the preclinical development of the company’s...
Shock: Adrenomed AG gets FDA fast track designation
After Adrenomed AG has demonstrated that its septic shock treatment led to a 60% reduction in relative 28-day mortality vs. placebo in a stratified...